Overview

Diabetes Remote Intervention to improVe Use of Evidence-based Medications

Status:
COMPLETED
Trial end date:
2023-07-25
Target enrollment:
Participant gender:
Summary
A randomized remote, implementation trial in the Mass General Brigham network was performed on 200 patients with T2D at high CV or kidney risk. The study's primary objective was to create a remote diabetes management platform that improved the initiation and adherence to glucose-lowering medications with CV and kidney benefit and was evaluated by the primary outcome: increasing the proportion of patients with prescriptions for GDMT therapy by 6 months.
Phase:
PHASE4
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
Novo Nordisk A/S
Treatments:
Sodium-Glucose Transporter 2 Inhibitors